TWI887310B - 艾薩妥昔單抗用於治療復發性和/或難治性多發性骨髓瘤的用途 - Google Patents

艾薩妥昔單抗用於治療復發性和/或難治性多發性骨髓瘤的用途 Download PDF

Info

Publication number
TWI887310B
TWI887310B TW109142973A TW109142973A TWI887310B TW I887310 B TWI887310 B TW I887310B TW 109142973 A TW109142973 A TW 109142973A TW 109142973 A TW109142973 A TW 109142973A TW I887310 B TWI887310 B TW I887310B
Authority
TW
Taiwan
Prior art keywords
treatment
individual
antibody
carfilzomib
dexamethasone
Prior art date
Application number
TW109142973A
Other languages
English (en)
Chinese (zh)
Other versions
TW202133880A (zh
Inventor
瑪麗 勞爾 里斯
蓋爾 艾薩特
Original Assignee
美商賽諾菲 安萬特美國有限責任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商賽諾菲 安萬特美國有限責任公司 filed Critical 美商賽諾菲 安萬特美國有限責任公司
Publication of TW202133880A publication Critical patent/TW202133880A/zh
Application granted granted Critical
Publication of TWI887310B publication Critical patent/TWI887310B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Ceramic Products (AREA)
TW109142973A 2019-12-06 2020-12-04 艾薩妥昔單抗用於治療復發性和/或難治性多發性骨髓瘤的用途 TWI887310B (zh)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201962944809P 2019-12-06 2019-12-06
US62/944,809 2019-12-06
EP20315186.5 2020-04-17
EP20315186 2020-04-17
US202063023198P 2020-05-11 2020-05-11
US63/023,198 2020-05-11
US202063037353P 2020-06-10 2020-06-10
US63/037,353 2020-06-10
US202063094833P 2020-10-21 2020-10-21
US63/094,833 2020-10-21

Publications (2)

Publication Number Publication Date
TW202133880A TW202133880A (zh) 2021-09-16
TWI887310B true TWI887310B (zh) 2025-06-21

Family

ID=74046182

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109142973A TWI887310B (zh) 2019-12-06 2020-12-04 艾薩妥昔單抗用於治療復發性和/或難治性多發性骨髓瘤的用途

Country Status (13)

Country Link
US (1) US20210171653A1 (https=)
EP (1) EP4069740A1 (https=)
JP (2) JP7704751B2 (https=)
KR (1) KR20220159948A (https=)
CN (1) CN115698065A (https=)
AU (1) AU2020398655A1 (https=)
BR (1) BR112022010907A2 (https=)
CA (1) CA3164026A1 (https=)
CO (1) CO2022009433A2 (https=)
IL (1) IL293615A (https=)
MX (1) MX2022006883A (https=)
TW (1) TWI887310B (https=)
WO (1) WO2021113754A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4536278A2 (en) 2022-06-07 2025-04-16 Actinium Pharmaceuticals, Inc. Bifunctional chelators and conjugates

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
JP6279065B2 (ja) * 2013-03-13 2018-02-14 サノフイ 抗ｃｄ３８抗体およびカーフィルゾミブを含む組成物
SG10201803288RA (en) * 2013-10-31 2018-05-30 Sanofi Sa Specific anti-cd38 antibodies for treating human cancers
JP2021502961A (ja) * 2017-10-31 2021-02-04 ヤンセン バイオテツク，インコーポレーテツド 高リスク多発性骨髄腫の治療方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
期刊 Chari, A., Martinez-Lopez, J., Mateos, M. V., Bladé, J., Benboubker, L., Oriol, A., ... & Moreau, P. Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma. Blood, The Journal of the American Society of Hematology 134(5) 2019 421-431

Also Published As

Publication number Publication date
US20210171653A1 (en) 2021-06-10
EP4069740A1 (en) 2022-10-12
JP2023505219A (ja) 2023-02-08
MX2022006883A (es) 2022-11-08
AU2020398655A1 (en) 2022-07-28
CA3164026A1 (en) 2021-06-10
JP2025138745A (ja) 2025-09-25
JP7704751B2 (ja) 2025-07-08
CN115698065A (zh) 2023-02-03
WO2021113754A1 (en) 2021-06-10
KR20220159948A (ko) 2022-12-05
TW202133880A (zh) 2021-09-16
CO2022009433A2 (es) 2022-07-29
IL293615A (en) 2022-08-01
BR112022010907A2 (pt) 2022-10-18

Similar Documents

Publication Publication Date Title
US20240190984A1 (en) Methods of treating multiple myeloma
JP2023542289A (ja) 濾胞性リンパ腫を治療するための併用療法におけるｃｄ３及びｃｄ２０に対する二重特異性抗体
CN114630842A (zh) 用于癌症治疗的结合her2、nkg2d和cd16的多特异性结合蛋白的药物制剂和剂量方案
JP2023542290A (ja) 濾胞性リンパ腫を治療するための併用療法におけるｃｄ３及びｃｄ２０に対する二重特異性抗体
JP7801132B2 (ja) 抗ｃｄ３８抗体を投与して多発性骨髄腫を処置する方法
JP2023542291A (ja) びまん性大細胞型ｂ細胞リンパ腫を治療するための併用療法におけるｃｄ３及びｃｄ２０に対する二重特異性抗体
JP2025138745A (ja) 再発性および／または不応性の多発性骨髄腫の処置のためのイサツキシマブの使用
TW202541838A (zh) 抗ｃｄ３８抗體在治療新診斷的多發性骨髓瘤中之用途
TWI922320B (zh) 艾薩妥昔單抗用於治療復發性和/或難治性多發性骨髓瘤的用途
US20250177519A1 (en) Use of isatuximab in combination with other agents for the treatment of multiple myeloma
TW202504915A (zh) 以抗ｃｄ３及ｃｄ２０之雙特異性抗體治療淋巴瘤之方法
RU2858309C2 (ru) Применение изатуксимаба для лечения рецидивирующей и/или рефрактерной множественной миеломы
TW202345895A (zh) 在用於治療瀰漫性大型ｂ細胞淋巴瘤之組合療法中針對ｃｄ３和ｃｄ２０之雙特異性抗體
CA3048198A1 (en) Methods of treating multiple myeloma
RU2838203C2 (ru) Способы лечения множественной миеломы
TW202529817A (zh) 用於治療癌症之組合療法
WO2025094087A1 (en) Safe administration of a2a rector antagonist